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Evaluating the Role of Fecal Microbiota Transplant in the
Treatment of Clostridium Difficile Infection
Anh Dao Le, Olivia Henton, Shane Bogusz, Brian Heilbronner, Jessica Hinson, PharmD

Abstract
Fecal microbiota transplant (FMT) therapy is an increasingly
prevalent treatment option for Clostridium difficile infection
(CDI). Clostridium difficile infection is an aggressive and potentially fatal disease state, and antibiotic therapy often fails to
resolve the disease state effectively. Clostridium difficile infection occurs most commonly subsequent to the use of antimicrobial agents that disrupt the natural bacterial flora of the
gastrointestinal (GI) tract Since disease state pathophysiology
operates in this way, researchers have experimented with
ways to restore GI flora to a natural state in which nonpathogenic bacteria can proliferate. Probiotic agents do not impose
an acute enough response to recreate typical GI tract flora,
which has led to experimentation with direct supplementation
of GI bacteria, thus underlying the purpose of FMT therapy.
Presently, FMT has demonstrated unparalleled efficacy in re:solving CDI and is poised to become first-line therapy as the
;body of evidence supporting its use continues to grow. This
·review examines the mechanism of action for FMT therapy
1and evaluates the results of clinical trials that have tested FMT
:therapy. Finally, the potential role for pharmacists in the management of patients with CDI will be discussed. Research has
'supported both the expanded use of FMT therapy in CDI and
·the establishment of standard practices for administering FMT
'. therapy in hospitals treating larger numbers of CDI patients.
:Furthermore, additional clinical trials that could supplement
existing support for FMT therapy are currently recruiting pa:tients.
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Background
The gastrointestinal (GI) tract comprises more than 500
species of intestinal microbiota, serving the functions of protection, structural support and metabolism to maintain homeostasis.1 Antibiotics are utilized to treat infectious diseases states; however, long-term use of antibiotics poses the risk
of causing digestive adverse effects such as cramping, gas or
diarrhea, due to nonselective eradication of bacteria and protective intestinal microbiota.2 Overutilization of antibiotics
may also increase the risk of Clostridium difficile infection
(CDI).1 Clostridium difficile infection is caused by Clostridium difficile (C. difficile), a gram positive, rod-shaped, sporeforming bacteria that is transmitted via the fecal-oral route
through direct and indirect contact. Subsequent to their inadvertent ingestion, C. difficile spores survive gastric acid and
proceed to the small intestine where they colonize and rapidly proliferate under anaerobic conditions. Proliferation and

22

subsequent CDI may be further exacerbated by the coadministration of antibiotics, which additionally displace and eradicate the homeostatic functions of normal GI flora.
The infectious symptomatology of C. difficile originates from
the bacterial spore which releases specific toxins, Toxin A
and Toxin B, that progress to Gl cellsP Toxin A is an enterotoxin which alters GI mucosa! epithelium cell permeability,
allowing fluid secretion, whereas Toxin B is a cytotoxin that
induces mucosa) inflammation in the colon. The inflammation causes increased GI permeability and motility, which
allows more granulocytes and fluid in the GI tract, resulting
in antibiotic-induced diarrhea. Alterations in cellular function and structure from the toxins also initiate cellular response and apoptosis, further damaging the GI tract.
According to the guidelines for diagnosis, treatment and prevention of C. difficile infections, diagnostic testing for confirmation of CD! should occur prior to treatment for patients
who do not present strong pre-test suspicion for CDJ.3 Diagnostic techniques include testing the suspected patient's
stool using laboratory tests and diagnostic imaging, the most
common of which include toxin enzyme immunoassays,
toxigenic cultures, nucleic acid amplification tests and the
C. difficile cytotoxin neutralization assay.4 GI structural remodeling can be observed by diagnostic colonoscopy and
computed tomography of the abdomen and pelvis.
The recommended first-line treatment for mild CDI is metronidazole 500 mg three times daily for 10 to 14 days.3 If resolution of symptoms does not occur within five to seven days,
oral vancomycin 125 mg four times daily for 10 days should
be administered. Patients who experience recurrence of CD!
within eight weeks of therapy are classified as having recurrent infection (RCDI), and approximately 20 percent of CDI
patients in mid-pharmacologic therapy for CDI treatment
experience a recurrence of the infection within six months of
therapy. For patients with RCDI, treatment with metronidazole or a vancomycin pulse regimen (every two to three day
dosing) is initially recommended. Fecal microbiota transplant (FMT) is then recommended after three recurrences of
infection within six months after discontinuing therapy. The
use of FMT is to establish normal GI flora composition, metabolism and upregulate immune responses in the mucosa.
Fecal microbiota transplant is used due to its safety, efficacy
and perceived cost-effectiveness.
Fecal Microbiota Transplant: Treatment Procedure,
Efficacy and Safety
Fecal microbiota transplant is a procedure during which
stool from a healthy patient is infused into a patient with
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RCDI. The rationale behind the treatment is based on RCDl
and the loss of homeostasis of GI flora, and the stool from
healthy patients can reintroduce normal flora to reestablish
homeostasis.4 The procedure calls for a stool sample from a
healthy donor to be prepared with normal saline and administered into the GI tract of the patient with CDI.S Patients
should be placed in the right lateral recumbent position and
hold this position throughout the implantation in order to
facilitate the optimum permanence of the fecal solution into
the colon. The procedure lasts about 10 minutes. The tube is
then removed, but patients are monitored during recovery
for approximately two hours.
Various methods of FMT administration exist, including nasogastric tube, naso-duodenal tube, colonoscopy, oral fecal capsules and self-administered enemas.s The most common and
advantageous route is via colonoscopy due to its ability to
spread the stool throughout the length of the colon extensively. Accessing the colon also allows the physician to observe
abnormalities in the colon. This route has yielded 86 percent
to 100 percent successful outcomes.
Given the limited understanding of the short-term and longterm effects of FMT, there are only a few studies that have
investigated the potential effects of transplanted microbiota
on recipient patients. In one cohort study by Song and colleagues at the University of Maryland's School of Medicine, 14
RCDI patients underwent FMT along with their respective
healthy donor as subjects.6 The fecal specimens of both populations were analyzed before FMT, as well as one week and
one year post-FMT to determine if the recipient's recovered
intestinal microbiota would mirror that of the donor's after
an extended period of time. Patients recovered symptomatically within two to three days of undergoing· FMT and were
classified as asymptomatic based upon resolution of diarrhea.
The fecal specimens of RCDI patients collected prior to FMT
displayed low diversity in microbial species when compared
to the samples given by healthy donors. The species present
in each sample were determined using rarefaction analysis of
operational taxonomic units, a method that utilizes DNA to
determine the presence of types of species. One week after
FMT, patients displayed an increase in microbial species, determined using Shannon diversity index calculations, a set of
calculations used to determine how proportional a multiple
species are in a given environment. Furthermore, the study
discovered that species diversity and species richness remained constant over time: fecal specimens collected one
year after FMT illustrated constant Shannon diversity scores.
More specifically, recipient microbiota not only increased in
diversity but also matched the composition of the donor in
most patient cases. However, multiple subjects did experience a transient return to a microbiota composition that resembled the patient's pre-FMT specimen collection. Despite
this regression on a microbial level, all patients experienced a
resolution of symptoms. One patient relapsed one month after the initial FMT following antibiotic treatment for a urinary
tract infection but underwent a second, successful FMT. This
data suggests that asymptomatic patients are still more susceptible to a C. difficile infection than healthy individuals folSpring 2016 Volume 7, Issue 2
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lowing administration of antibiotics despite an evolved microbiota. This study supported FMT for treatment of C. difficile infections presenting evidence that FMT treatment improved the micro biota composition of RCDI patients.
Another cohort study that investigated a similar parameter
was conducted by researchers of Wright State School of Medicine.7 Three RCDI patients received fecal matter from the
same healthy donor and fecal specimens were collected from
the three subjects as well as the donor prior to the FMT procedure. Specimens subsequently were collected from patients
on days three and seven following the treatment and
throughout a four month post-FMT period. Similar to the results found by Song and colleagues, all three patients experienced a resolution of symptoms characteristic to a C. difficile
infection only days after FMT. Two of the three patients reported to have a firm bowel movement on day three following the FMT procedure. The same two patients remained free
of infection for approximately two years following FMT; the
third patient, who also suffered from ulcerative colitis, experienced an infection of C. difficile 1.5 years following treatment after taking antibiotics for an unrelated urinary tract
infection. Specimens obtained from patients prior to FMT
illustrated low species diversity. The composition of the
healthy donor was diverse, and the abundance of organisms
was even with regard to each species. The study found a pattern in the type of species that existed in patients pre-FMT
compared to that found in the donor. The three recipients had
specimens containing high levels of organisms belonging to
the classes gammaproteobacteria and bacilli. These microbial
classes are able to withstand the presence of oxygen as C. difficile infections often lead to an infiltration of reactive oxygen
species. In contrast, the study reported that the donor's fecal
matter were dominated by bacteria in Clostridia, Actinobacteria, Erysipelotrichi and Bacteroidia, classes that typically
comprise the GI tract of a healthy human. Following FMT, the
three patients displayed an increase in bacteria from classes
Bacteroidia and Clostridia which remained stable over the
four month period following treatment. The patients' preFMT fecal compositions were reportedly variable and distinct
from each other. Following FMT, however, the three subjects'
samples paralleled the donor sample. This study concluded
that the composition of the subjects' micro biota prior to FMT
did not affect the outcome or microbial makeup following
treatment and confirmed the efficacy of FMT on a long-term
basis. This finding provides clinical significance in the outcome of FMT; the change in microbial makeup parallels the
patients' reduction of symptoms, including diarrhea.

Comparison of Fecal Microbiota Transplant, Antibiotics
and Combination Therapy in Treating Clostridium
Difficile Infection
Several studies and randomized control trials have evaluated
the efficacy of FMT in comparison to traditional pharmacologic treatment modalities, specifically comparing FMT alone
or as an adjunct therapy with antibiotics to antibiotic monotherapy. s,s,9 Catholic University School of Medicine conducted
an open-label, randomized clinical trial comparing the thera-
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pies of FMT via colonoscopy in patients with recurrent CDI
versus pharmacologic vancomycin therapy.s Twenty patients
diagnosed with C. difficile were treated with 125 mg vancomycin tablets four times a day for three days, followed by
one or more infusions of feces until the conclusion of 10
weeks. Nineteen patients were treated with 125 mg vancornycin four times a day for 10 days, followed by pulse therapy of 125 to 500 mg/day every two to three days for at least
three weeks. Results showed 18 of the 20 patients treated by
FMT with vancomycin short term pretreatment no longer
suffered from diarrhea. Only five of the 19 patients treated
with vancomycin alone (P < 0.0001) were treated successfully. The researchers concluded that FMT via colonoscopy is
more effective than vancomycin therapy in treatment of CDI.
Another randomized, control trial compared traditional antibiotic use with FMT. Els van Nood and colleagues conducted
a study using duodenal infusion of feces versus a typical 14
day vancomycin treatment for CDJ.B Three dependent groups
in the trial were included: patients who were given an initial
vancomycin regimen of 500 mg orally four times a day for a
duration of four days then underwent a bowel lavage,
followed by infusion fecal; patients who were given the
standard vancomycin regimen followed by bowel lavage; and
patients who were just given the standard vancomycin regimen. Patients were randomly assigned to one of these groups
with the primary end point of curing RCDI with absence of
relapse within 10 weeks. Sixteen patients were in the infusion group and 13 patients (81 percent) met the primary end
point. The remaining three patients who did not show resolution underwent a second infusion, and two patients had
successful resolution (P < 0.001) . The group that received the
bowel lavage had three successful resolutions within 13 patients (23 percent). The group that only received standard
vancomycin regimen yielded four successful resolutions out
of 13 patients (31 percent). Researchers concluded that infusion donor feces is more efficacious in comparison to vancomycin in RCDI treatment.
Researchers of the Harvard School of Public Health conducted a retrospective review of the long-term effects of multiple
FMT treatments in patients with RCDl.9 The review involved
94 RCDI patients total; 45 subjects were cured (defined as
having not experienced diarrhea incidents for six consecutive
months) after one single FMT treatment. The remaining patients received multiple FMTs, the highest number of which
was 10 FMTs. Patients receiving multiple FMTs were given
antibiotics between each treatment which resulted in a 5.3
percent increase in the resolution rate; thus, the subsequent
treatment was more successful. Patients considered cured
following FMT were reported to be free of C. difficile infection for an additional period of six to 24 months. The study
resulted in an absence of adverse events as a result of FMT
therapy. The authors reported a 92 percent cure rate among
patients who underwent FMT with additional antibiotic therapy. Researchers concluded that FMT is an effective treatment for RCDI not resolved by antibiotic therapy and is safe
when completed multiple times on a single patient.
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The Role of the Pharmacist in FMT: Post-treatment and
Prevention of Recurrent Clostridium Difficile Infection
Despite the impressive reported cure rates of C. difficile infections treated with FMT, there remains a major risk of disease recurrence. A retrospective study that surveyed CDI
patients treated with FMT found that diarrhea recurred in 29
percent of patients, although the time window for recurrence
was three years in some documented cases.10 Of the 22 total
patients with documented recurrent diarrhea, seven (32 percent) experienced self-limited diarrhea, thus not attributable
to recurrent CDI. The significant risk of disease recurrence
therefore presents an opportunity and obligation for medical
professionals to provide patient education to CDI patients
upon their release from institutional care. In the outpatient
setting, pharmacists have an opportunity to counsel patients
recovering from CDI by distinguishing between nonpathogenic self-limiting diarrhea and diarrhea associated with CD!
recurrence, which requires rehospitalization. Specifically,
CDI-related diarrhea is associated with a foul smelling, watery nature as well as fever and abdominal pain.11
Another opportunity for pharmacists to help in the prevention of CDI involves promoting antibiotic stewardship and
appropriate adherence to antibiotic regimens. Alternative
antibiotic therapies should be considered in patients prescribed antibiotics with high rates of causing CDI. Antibiotics
considered to be highest risk for causing CDI include ciprofloxacin, levofloxacin, moxifloxacin, clindamycin, ceftriaxone,
cefotaxime, ceftazidime and cefixime.12 When conducting
medication reviews, pharmacists should be mindful of the
use of high-risk antibiotics in both patients with previous CD!
and patients belonging to general demographics with increased risk of CD!. Several patient groups that may warrant
additional attention for CD! prevention include patients in
hospitals with ongoing CDI outbreaks, geriatric patients,
those taking multiple different antibiotics in a brief window
of time and patients admitted for an unrelated infection.13 A
2014 meta-analysis of antibiotic stewardship programs and
CD! risk found a relative risk for CD! of 0.48 for patients who
participated in such a program.14 Antibiotic stewardship is a
valuable intervention that, when implemented appropriately,
can prevent thousands of cases of CD! every year.
Researchers have investigated the use of proton pump inhibitors (PPis) alongside high-risk antibiotics and found that PPI
use represents a significant risk factor for CD! with a relative
risk of 2.2 (95 percent CI: 1.52-3.23; p = 0.0001).12 This retrospective cohort study by Gordon and colleagues assessed
how CDI incidence in a population of U.S. veterans was related to PPI use. Although the 20,944 patient medical records
included only 111 documented cases of CD!, sufficient statistical significance demonstrated a clear additional risk with
PPI use in patients receiving antibiotics known to increase
CD! susceptibility. Further, Gordon and colleagues reaffirmed
the high-risk status of the antibiotics investigated, particularly clindamycin and ciprofloxacin, which were most likely to
produce CDI. With this in mind, pharmacists should seek to
identify patients taking both PPis and high-risk antibiotics
and attempt a therapeutic substitution when possible. Since
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certain PPls are available over-the-counter, the patient's
physician may not be aware of this medication use. Pharmacists should counsel patients taking PPls for extended periods of time, and should remain vigilant for cases of patients
on high-risk antibiotics taking either prescribed or over-thecounter PPls.11

Conclusion
Fecal microbiota transplant exerts its therapeutic action by
restoring intestinal nonpathogenic bacteria to produce a
state more closely resembling the GI flora of the fecal matter
donor. Preliminary research suggests a superiority of FMT
over antibiotic therapy in treatment of C. difficile infection.
Though comparative trials between the two therapies are
limited in scope and number, FMT produced disease state
resolution in 81 percent and 90 percent of patients, while
antibiotic therapy attained such success in only 26 percent
and 23 percent of patients, respectively.s When the two
therapies were combined, with intermittent antibiotics
administered between multiple FMTs, a synergistic effect
was produced by the combination therapy with a successful
treatment rate of 92 percent. Additional trials are currently
recruiting patients to increase the strength of the evidence
supporting increased use of FMT in treating CD!, but the direction of preliminary research indicates that FMT is a safe,
effective treatment with superiority to antibiotics alone.
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